The role of PET in dementia diagnosis and treatment

Applied Radiology

Volumn 41, Issue 5, 2012, Pages 8-15

  Mehta, Lina ^a   Thomas, Smitha ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CYSTEINE ETHYL ESTER TC 99M; DIHYDROTETRABENAZINE; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; MEMANTINE; PITTSBURGH COMPOUND B;

ALZHEIMER DISEASE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DSM-IV; DSM-IV-TR; FRONTOTEMPORAL DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84860666329     PISSN: 01609963     EISSN: 18792898     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kertesz A. Pick Complex: An integrative approach to frontotemporal dementia: Primary progressive aphasia, corticobasal degeneration, and progressive supranuclear palsy. Neurologist. 2003;9:311-317.
2. Kertesz A, Hudson L, Mackenzie IR, Munoz DG. The pathology and nosology of primary progressive aphasia. Neurology. 1994;44:2065-2072.
3. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112-2117.
4. DSM-IV-TR: The Current Manual. http://www.psych.org/MainMenu/Research/DSMIV/DSMIVTR.aspx. Accessed January 13, 2011.
5. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594-607.
6. Zhu CW, Sano M. Economic considerations in the management of Alzheimer's disease. Clin Interv Aging. 2006;1:143-154.
7. General Information. http://www.nia.nih.gov/Alzheimers/AlzheimersInformation/GeneralInfo/. Accessed January 13, 2011.
8. Schuff N, Zhu XP. Imaging of mild cognitive impairment and early dementia. Br J Radiol. 2007;80 Spec No 2:S109-14.
9. Silverman DH, Cummings JL, Small GW, et al. Added clinical benefit of incorporating 2-deoxy- 2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002;4:283-293.
10. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41: 1920-1928.
11. Yamaguchi S, Meguro K, Itoh M, et al. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. J Neurol Neurosurg Psychiatry. 1997;62:596-600.
12. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49: 390-398.
13. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230-238.
14. Patwardhan MB, McCrory DC, Matchar DB, et al. Alzheimer disease: Operating characteristics of PET--a meta-analysis. Radiology. 2004;231:73-80.
15. Morinaga A, Ono K, Ikeda T, et al. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Dement Geriatr Cogn Disord. 2010;30:285-292.
16. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. J Nucl Med. 2002;43:253-266.
17. Centers for Medicare & Medicaid Services. http://www.cms.gov/mcd/viewncd.asp?ncd_id=220.6.13&ncd_version=2&basket=ncd:220.6.13:2:PET+(FDG)+for+Dementia+and+Neurodegenerative+Diseases. Accessed January 13, 2011.
18. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127.
19. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638-1645.
20. Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50: 358-365.
21. Jokinen P, Scheinin N, Aalto S, et al. [(11) C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord. 2010;16:666-670.
22. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4:771-780.
23. Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: A longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28: 42-50.
24. Jack CR, Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336-3348.
25. Koeppe RA, Gilman S, Junck L, et al. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)- [11C] dihydrotetrabenazine positron emission tomography. Alzheimers Dement. 2008;4(1 Suppl 1):S67-76.